Key Highlights

  • The stock is priced near $413.58, representing a decline of about 26.71% and sits roughly 27% beneath the $560 target.
  • Analysts’ base‑case price of $559.79 points to a 35.35% upside; the broader Wall Street consensus is slightly higher at $563.35.
  • Q1 2026 non‑GAAP EPS of $2.50 outperformed the $2.11 consensus by roughly 18.66%, and revenue rose 23% YoY to $2.77 billion.
  • Operating income surged 47.95% as Da Vinci procedures increased ~16% and Ion procedures grew ~39%.

Intuitive Surgical (NASDAQ: ISRG) is reshaping expectations for the healthcare sector as its shares hover about 27% below a $560 target. This discount, combined with a streak of earnings surprises, has drawn attention from investors seeking exposure to medical‑device growth.

What Happened

In the first quarter of 2026, the company reported non‑GAAP earnings of $2.50 per share, beating the $2.11 consensus by roughly 18.66%. Revenue climbed to $2.77 billion, marking a 23% increase from the same period last year, while operating income jumped 47.95%. Procedure volumes continued their upward trajectory, with Da Vinci surgeries rising approximately 16% and Ion system usage expanding about 39%.

The installed base now totals 11,395 units, including 1,041 Ion systems that contributed $1.69 billion in revenue.

Market Impact

Analyst coverage has been revised upward, with a base‑case target of $559.79, indicating roughly a 35.35% upside, and a Wall Street consensus slightly higher at $563.35. The current trading level of $413.58, reflecting a decline of about 26.71%, positions the company as a notable holding in many retirement portfolios focused on healthcare. Cash balances have risen to $7.98 billion, underscoring a strong balance sheet.

The firm has also pursued share‑repurchase activity, reinforcing confidence among institutional investors. Competitors, such as Medtronic, continue to face challenges against ISRG’s extensive installed base.

What’s Next

The upcoming earnings release on July 16 is expected to be a pivotal catalyst. Analysts project procedure growth of up to 17.5% for the next quarter, aligning with management’s outlook. Polymarket assigns a 97% probability to the earnings event, reflecting broad market expectation of continued outperformance.

Operating income growth of about 25% for FY2025 further supports the compounding narrative that supports the sizable upside potential.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.